{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:50:10Z","timestamp":1789411810814,"version":"build-2803163510"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s11912-019-0797-z","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T10:54:29Z","timestamp":1554375269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies"],"prefix":"10.1007","volume":"21","author":[{"given":"Isaac B.","family":"Rhea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Fradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"issue":"2","key":"797_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1001\/archinte.1954.00250020047003","volume":"94","author":"DV Clatanoff","year":"1954","unstructured":"Clatanoff DV, Triggs PO, Meyer OO. Clinical experience with coumarin anticoagulants warfarin and warfarin sodium. AMA Arch Intern Med. 1954;94(2):213\u201320.","journal-title":"AMA Arch Intern Med"},{"issue":"14","key":"797_CR2","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1517\/14656566.9.14.2509","volume":"9","author":"H Nishio","year":"2008","unstructured":"Nishio H, Ieko M, Nakabayashi T. New therapeutic option for thromboembolism--dabigatran etexilate. Expert Opin Pharmacother. 2008;9(14):2509\u201317. \n                      https:\/\/doi.org\/10.1517\/14656566.9.14.2509\n                      \n                    .","journal-title":"Expert Opin Pharmacother"},{"issue":"38","key":"797_CR3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893\u2013962. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehw210\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"2","key":"797_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/cncr.26304","volume":"118","author":"MA Escobar","year":"2012","unstructured":"Escobar MA. Bleeding in the patient with a malignancy: is it an acquired factor VIII inhibitor? Cancer. 2012;118(2):312\u201320. \n                      https:\/\/doi.org\/10.1002\/cncr.26304\n                      \n                    .","journal-title":"Cancer."},{"issue":"8","key":"797_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrclinonc.2012.106","volume":"9","author":"A Young","year":"2012","unstructured":"Young A, Chapman O, Connor C, Poole C, Rose P, Kakkar AK. Thrombosis and cancer. Nat Rev Clin Oncol. 2012;9(8):437\u201349. \n                      https:\/\/doi.org\/10.1038\/nrclinonc.2012.106\n                      \n                    .","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"797_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","volume":"6","author":"P Prandoni","year":"2005","unstructured":"Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6(6):401\u201310. \n                      https:\/\/doi.org\/10.1016\/S1470-2045(05)70207-2\n                      \n                    .","journal-title":"Lancet Oncol"},{"issue":"3","key":"797_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11606-006-0019-x","volume":"22","author":"CP Gross","year":"2007","unstructured":"Gross CP, Galusha DH, Krumholz HM. The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. J Gen Intern Med. 2007;22(3):321\u20136. \n                      https:\/\/doi.org\/10.1007\/s11606-006-0019-x\n                      \n                    .","journal-title":"J Gen Intern Med"},{"issue":"10","key":"797_CR8","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1200\/JCO.2005.03.133","volume":"23","author":"AY Lee","year":"2005","unstructured":"Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23(10):2123\u20139. \n                      https:\/\/doi.org\/10.1200\/JCO.2005.03.133\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"12","key":"797_CR9","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","volume":"119","author":"RD Hull","year":"2006","unstructured":"Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062\u201372. \n                      https:\/\/doi.org\/10.1016\/j.amjmed.2006.02.022\n                      \n                    .","journal-title":"Am J Med"},{"issue":"7","key":"797_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.9243","volume":"314","author":"AYY Lee","year":"2015","unstructured":"Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677\u201386. \n                      https:\/\/doi.org\/10.1001\/jama.2015.9243\n                      \n                    .","journal-title":"JAMA."},{"issue":"11","key":"797_CR11","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.6004\/jnccn.2013.0165","volume":"11","author":"PC Hendrie","year":"2013","unstructured":"Hendrie PC, Garcia DA. Are new oral anticoagulants ready for use in patients with cancer? J Natl Compr Cancer Netw. 2013;11(11):1446\u20139.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"36","key":"797_CR12","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1093\/eurheartj\/ehw385","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL. Specific risk of atrial fibrillation and stroke in oncology patients. Eur Heart J. 2016;37(36):2747\u20138. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehw385\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"1","key":"797_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-9560-11-21","volume":"11","author":"MH Prins","year":"2013","unstructured":"Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21. \n                      https:\/\/doi.org\/10.1186\/1477-9560-11-21\n                      \n                    .","journal-title":"Thromb J"},{"key":"797_CR14","doi-asserted-by":"publisher","unstructured":"Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev 2018;6:CD006650. \n                      https:\/\/doi.org\/10.1002\/14651858.CD006650.pub5\n                      \n                    .","DOI":"10.1002\/14651858.CD006650.pub5"},{"issue":"12","key":"797_CR15","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/jth.13153","volume":"13","author":"G Agnelli","year":"2015","unstructured":"Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13(12):2187\u201391. \n                      https:\/\/doi.org\/10.1111\/jth.13153\n                      \n                    .","journal-title":"J Thromb Haemost"},{"issue":"1","key":"797_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1160\/TH14-11-0977","volume":"114","author":"S Schulman","year":"2015","unstructured":"Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015;114(1):150\u20137. \n                      https:\/\/doi.org\/10.1160\/TH14-11-0977\n                      \n                    .","journal-title":"Thromb Haemost"},{"issue":"15","key":"797_CR17","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"VTEI Hokusai","year":"2013","unstructured":"Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406\u201315. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1306638\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"20","key":"797_CR18","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with Cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017\u201323. \n                      https:\/\/doi.org\/10.1200\/JCO.2018.78.8034\n                      \n                    .","journal-title":"J Clin Oncol"},{"key":"797_CR19","unstructured":"\u2022\u2022 National Comprehesive Cancer Network. Cancer-associated venous thromboembolic disease (Version 2.2018). \n                      https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vte.pdf\n                      \n                    . Accessed November 2, 2018. A useful set of guidelines that are frequently updated as new literature becomes available\n                              ."},{"issue":"6","key":"797_CR20","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","volume":"33","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654\u20136. \n                      https:\/\/doi.org\/10.1200\/JCO.2014.59.7351\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"2","key":"797_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315\u201352. \n                      https:\/\/doi.org\/10.1016\/j.chest.2015.11.026\n                      \n                    .","journal-title":"Chest."},{"issue":"8986","key":"797_CR22","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0140-6736(95)92339-X","volume":"346","author":"GY Lip","year":"1995","unstructured":"Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet. 1995;346(8986):1313\u20134.","journal-title":"Lancet."},{"issue":"12","key":"797_CR23","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0894-7317(99)70105-7","volume":"12","author":"ME Goldman","year":"1999","unstructured":"Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (the stroke prevention in atrial fibrillation [SPAF-III] study). J Am Soc Echocardiogr. 1999;12(12):1080\u20137.","journal-title":"J Am Soc Echocardiogr"},{"issue":"8","key":"797_CR24","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","volume":"70","author":"BB Navi","year":"2017","unstructured":"Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70(8):926\u201338. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2017.06.047\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"key":"797_CR25","doi-asserted-by":"publisher","first-page":"j5058","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA Lopez-Lopez","year":"2017","unstructured":"Lopez-Lopez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058. \n                      https:\/\/doi.org\/10.1136\/bmj.j5058\n                      \n                    .","journal-title":"BMJ."},{"key":"797_CR26","doi-asserted-by":"publisher","first-page":"CD009447","DOI":"10.1002\/14651858.CD009447.pub3","volume":"7","author":"CF Matar","year":"2018","unstructured":"Matar CF, Kahale LA, Hakoum MB, Tsolakian IG, Etxeandia-Ikobaltzeta I, Yosuico VE, et al. Anticoagulation for perioperative thromboprophylaxis in people with cancer. Cochrane Database Syst Rev. 2018;7:CD009447. \n                      https:\/\/doi.org\/10.1002\/14651858.CD009447.pub3\n                      \n                    .","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"797_CR27","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1161\/STROKEAHA.110.590257","volume":"41","author":"GY Lip","year":"2010","unstructured":"Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41(12):2731\u20138. \n                      https:\/\/doi.org\/10.1161\/STROKEAHA.110.590257\n                      \n                    .","journal-title":"Stroke."},{"issue":"21","key":"797_CR28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1\u201376. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2014.03.022\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"797_CR29","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","volume":"33","author":"L Friberg","year":"2012","unstructured":"Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J. 2012;33(12):1500\u201310. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehr488\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"2","key":"797_CR30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.thromres.2015.06.011","volume":"136","author":"G Denas","year":"2015","unstructured":"Denas G, Pengo V, Joppi R, Prandoni P. Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy. Thromb Res. 2015;136(2):488. \n                      https:\/\/doi.org\/10.1016\/j.thromres.2015.06.011\n                      \n                    .","journal-title":"Thromb Res"},{"key":"797_CR31","doi-asserted-by":"publisher","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Jr., Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society . J Am Coll Cardiol 2019. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2019.01.011\n                      \n                    .","DOI":"10.1016\/j.jacc.2019.01.011"},{"issue":"8","key":"797_CR32","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1161\/CIRCULATIONAHA.117.029081","volume":"137","author":"PB Nielsen","year":"2018","unstructured":"Nielsen PB, Skjoth F, Overvad TF, Larsen TB, Lip GYH. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc? Circulation. 2018;137(8):832\u201340. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.029081\n                      \n                    .","journal-title":"Circulation."},{"issue":"6","key":"797_CR33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1177\/2047487318759858","volume":"25","author":"M D\u2019Souza","year":"2018","unstructured":"\u2022 D\u2019Souza M, Carlson N, Fosbol E, Lamberts M, Smedegaard L, Nielsen D, et al. CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol. 2018;25(6):651\u20138. \n                      https:\/\/doi.org\/10.1177\/2047487318759858\n                      \n                     An excellent study remarking on how the CHA2DS2-VASc score may not be ideal in cancer patients.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"797_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ijcard.2012.08.036","volume":"165","author":"YF Hu","year":"2013","unstructured":"Hu YF, Liu CJ, Chang PM, Tsao HM, Lin YJ, Chang SL, et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol. 2013;165(2):355\u20137. \n                      https:\/\/doi.org\/10.1016\/j.ijcard.2012.08.036\n                      \n                    .","journal-title":"Int J Cardiol"},{"issue":"12","key":"797_CR35","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/j.amjcard.2017.08.038","volume":"120","author":"R Patell","year":"2017","unstructured":"Patell R, Gutierrez A, Rybicki L, Khorana AA. Usefulness of CHADS2 and CHA2DS2-VASc scores for stroke prediction in patients with cancer and atrial fibrillation. Am J Cardiol. 2017;120(12):2182\u20136. \n                      https:\/\/doi.org\/10.1016\/j.amjcard.2017.08.038\n                      \n                    .","journal-title":"Am J Cardiol"},{"key":"797_CR36","unstructured":"Pradaxa (dabigitran etexilate mesylatete) [package insert]. Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield, CT. 2018."},{"key":"797_CR37","volume-title":"Bristol-Myers Squibb company","author":"Eliquis (apixiban) [package insert]","year":"2018","unstructured":"Eliquis (apixiban) [package insert]. Bristol-Myers Squibb company. Princeton: NJ; 2018."},{"key":"797_CR38","unstructured":"Xarelto (rivaroxaban) [package insert]. Janssen Pharmaceuticals Inc, Titusville, NJ. 2018."},{"key":"797_CR39","volume-title":"Daiichi Sankyo Co","author":"Savaysa (edoxaban) [package insert]","year":"2017","unstructured":"Savaysa (edoxaban) [package insert]. Daiichi Sankyo Co. Tokyo, Japan: LTD; 2017."},{"issue":"12","key":"797_CR40","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","volume":"130","author":"C Melloni","year":"2017","unstructured":"Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med. 2017;130(12):1440\u20138 e1. \n                      https:\/\/doi.org\/10.1016\/j.amjmed.2017.06.026\n                      \n                    .","journal-title":"Am J Med"},{"issue":"16","key":"797_CR41","doi-asserted-by":"publisher","first-page":"e008987","DOI":"10.1161\/JAHA.118.008987","volume":"7","author":"CL Fanola","year":"2018","unstructured":"\u2022 Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, et al. Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial. J Am Heart Assoc. 2018;7(16):e008987. \n                      https:\/\/doi.org\/10.1161\/JAHA.118.008987\n                      \n                     An interesting sub-analysis of the large ENGAGE-AF showing the benefit of edoxaban in cancer patients.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"797_CR42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","volume":"2","author":"S Shah","year":"2018","unstructured":"Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2(3):200\u20139. \n                      https:\/\/doi.org\/10.1182\/bloodadvances.2017010694\n                      \n                    .","journal-title":"Blood Adv"},{"issue":"6","key":"797_CR43","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cam4.1054","volume":"6","author":"AG Ording","year":"2017","unstructured":"Ording AG, Horvath-Puho E, Adelborg K, Pedersen L, Prandoni P, Sorensen HT. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med. 2017;6(6):1165\u201372. \n                      https:\/\/doi.org\/10.1002\/cam4.1054\n                      \n                    .","journal-title":"Cancer Med"},{"issue":"2","key":"797_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146\u201353. \n                      https:\/\/doi.org\/10.1056\/NEJMoa025313\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"2","key":"797_CR45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"GY Lip","year":"2011","unstructured":"Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal\/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs\/alcohol concomitantly) score. J Am Coll Cardiol. 2011;57(2):173\u201380. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2010.09.024\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"797_CR46","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00277-011-1267-3","volume":"90","author":"P Loewen","year":"2011","unstructured":"Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol. 2011;90(10):1191\u2013200. \n                      https:\/\/doi.org\/10.1007\/s00277-011-1267-3\n                      \n                    .","journal-title":"Ann Hematol"},{"issue":"3","key":"797_CR47","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","volume":"159","author":"RD Lopes","year":"2010","unstructured":"Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331\u20139. \n                      https:\/\/doi.org\/10.1016\/j.ahj.2009.07.035\n                      \n                    .","journal-title":"Am Heart J"},{"issue":"10","key":"797_CR48","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1009638\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"4","key":"797_CR49","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ajh.23122","volume":"87","author":"G Saccullo","year":"2012","unstructured":"Saccullo G, Malato A, Raso S, Santoro M, Zammit V, Casuccio A, et al. Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin. Am J Hematol. 2012;87(4):388\u201391. \n                      https:\/\/doi.org\/10.1002\/ajh.23122\n                      \n                    .","journal-title":"Am J Hematol"},{"issue":"2","key":"797_CR50","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40264-014-0258-4","volume":"38","author":"J Tamargo","year":"2015","unstructured":"Tamargo J, Caballero R, Delpon E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 2015;38(2):129\u201352. \n                      https:\/\/doi.org\/10.1007\/s40264-014-0258-4\n                      \n                    .","journal-title":"Drug Saf"},{"issue":"6","key":"797_CR51","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/clc.20904","volume":"34","author":"V Feliz","year":"2011","unstructured":"Feliz V, Saiyad S, Ramarao SM, Khan H, Leonelli F, Guglin M. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34(6):356\u20139. \n                      https:\/\/doi.org\/10.1002\/clc.20904\n                      \n                    .","journal-title":"Clin Cardiol"},{"issue":"6","key":"797_CR52","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2217\/fon.14.51","volume":"10","author":"MS Davids","year":"2014","unstructured":"Davids MS, Brown JR. Ibrutinib: a first in class covalent inhibitor of Bruton\u2019s tyrosine kinase. Future Oncol. 2014;10(6):957\u201367. \n                      https:\/\/doi.org\/10.2217\/fon.14.51\n                      \n                    .","journal-title":"Future Oncol"},{"issue":"10","key":"797_CR53","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"JR Brown","year":"2017","unstructured":"Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796\u2013805. \n                      https:\/\/doi.org\/10.3324\/haematol.2017.171041\n                      \n                    .","journal-title":"Haematologica"},{"issue":"3","key":"797_CR54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213\u201323. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1400376\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"797_CR55","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1182\/blood.V126.23.2933.2933","volume":"126","author":"M Farooqui","year":"2015","unstructured":"Farooqui M, Valdez J, Soto S, Bray A, Tian X, Wiestner A. Atrial fibrillation in CLL\/SLL patients on Ibrutinib. Blood. 2015;126:2933.","journal-title":"Blood."},{"issue":"1","key":"797_CR56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-018-0626-0","volume":"11","author":"G Reda","year":"2018","unstructured":"Reda G, Fattizzo B, Cassin R, Mattiello V, Tonella T, Giannarelli D, et al. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study. J Hematol Oncol. 2018;11(1):79. \n                      https:\/\/doi.org\/10.1186\/s13045-018-0626-0\n                      \n                    .","journal-title":"J Hematol Oncol"},{"issue":"1","key":"797_CR57","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","volume":"128","author":"DP Leong","year":"2016","unstructured":"\u2022 Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138\u201340. \n                      https:\/\/doi.org\/10.1182\/blood-2016-05-712828\n                      \n                     A thorough analysis of the relevant studies demonstrating the increased risk of atrial fibrillation with ibrutinib.","journal-title":"Blood."},{"issue":"3","key":"797_CR58","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","volume":"175","author":"L Pretorius","year":"2009","unstructured":"Pretorius L, Du XJ, Woodcock EA, Kiriazis H, Lin RC, Marasco S, et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol. 2009;175(3):998\u20131009. \n                      https:\/\/doi.org\/10.2353\/ajpath.2009.090126\n                      \n                    .","journal-title":"Am J Pathol"},{"issue":"25","key":"797_CR59","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829\u201330. \n                      https:\/\/doi.org\/10.1182\/blood-2014-10-604272\n                      \n                    .","journal-title":"Blood."},{"issue":"10121","key":"797_CR60","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659\u201367. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(17)33108-2\n                      \n                    .","journal-title":"Lancet."},{"issue":"26","key":"797_CR61","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","volume":"124","author":"M Levade","year":"2014","unstructured":"Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124(26):3991\u20135. \n                      https:\/\/doi.org\/10.1182\/blood-2014-06-583294\n                      \n                    .","journal-title":"Blood."},{"issue":"4","key":"797_CR62","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/leu.2014.247","volume":"29","author":"S Kamel","year":"2015","unstructured":"Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29(4):783\u20137. \n                      https:\/\/doi.org\/10.1038\/leu.2014.247\n                      \n                    .","journal-title":"Leukemia."},{"issue":"12","key":"797_CR63","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","volume":"100","author":"AH Lipsky","year":"2015","unstructured":"Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM, Nghiem K, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100(12):1571\u20138. \n                      https:\/\/doi.org\/10.3324\/haematol.2015.126672\n                      \n                    .","journal-title":"Haematologica."},{"issue":"6","key":"797_CR64","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1306220\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"797_CR65","unstructured":"Imbruvica: EPAR- product information [package insert]. Janssen Pharmaceutica NV, Beerse, Belgium. 2018."},{"key":"797_CR66","unstructured":"Imbruvica (ibrutinib) [package insert]. Pharmacyclics LLC, Sunnyvale, CA. 2018."},{"issue":"25","key":"797_CR67","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1509388\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"16","key":"797_CR68","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497\u2013506. \n                      https:\/\/doi.org\/10.1182\/blood-2014-10-606038\n                      \n                    .","journal-title":"Blood."},{"issue":"12","key":"797_CR69","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018;4(12):1491\u2013500. \n                      https:\/\/doi.org\/10.1016\/j.jacep.2018.06.004\n                      \n                    .","journal-title":"JACC Clin Electrophysiol"},{"issue":"15","key":"797_CR70","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","volume":"138","author":"KC Siontis","year":"2018","unstructured":"Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519\u201329. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035418\n                      \n                    .","journal-title":"Circulation"},{"issue":"9","key":"797_CR71","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40264-016-0443-8","volume":"39","author":"JL Fitzgerald","year":"2016","unstructured":"Fitzgerald JL, Howes LG. Drug interactions of direct-acting oral anticoagulants. Drug Saf. 2016;39(9):841\u20135. \n                      https:\/\/doi.org\/10.1007\/s40264-016-0443-8\n                      \n                    .","journal-title":"Drug Saf"},{"issue":"12","key":"797_CR72","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1080\/10428194.2017.1315115","volume":"58","author":"KL Chai","year":"2017","unstructured":"Chai KL, Rowan G, Seymour JF, Burbury K, Carney D, Tam CS. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. Leuk Lymphoma. 2017;58(12):2811\u20134. \n                      https:\/\/doi.org\/10.1080\/10428194.2017.1315115\n                      \n                    .","journal-title":"Leuk Lymphoma"},{"key":"797_CR73","volume-title":"Ca","author":"Andexxa (andrexanet alfa) [package insert]. Porola Pharmaceuticals Inc","year":"2018","unstructured":"Andexxa (andrexanet alfa) [package insert]. Porola Pharmaceuticals Inc. South San Francisco. In: Ca; 2018."},{"issue":"3","key":"797_CR74","doi-asserted-by":"publisher","first-page":"e0195122","DOI":"10.1371\/journal.pone.0195122","volume":"13","author":"G Lu","year":"2018","unstructured":"Lu G, Pine P, Leeds JM, DeGuzman F, Pratikhya P, Lin J, et al. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. PLoS One. 2018;13(3):e0195122. \n                      https:\/\/doi.org\/10.1371\/journal.pone.0195122\n                      \n                    .","journal-title":"PLoS One"},{"issue":"9","key":"797_CR75","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMoa1501035","volume":"373","author":"JD Douketis","year":"2015","unstructured":"Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823\u201333. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1501035\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"7","key":"797_CR76","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jacc.2016.11.024","volume":"69","author":"JU Doherty","year":"2017","unstructured":"Doherty JU, Gluckman TJ, Hucker WJ, Januzzi JL Jr, Ortel TL, Saxonhouse SJ, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017;69(7):871\u201398. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2016.11.024\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"797_CR77","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.jacc.2015.06.028","volume":"66","author":"FA Masoudi","year":"2015","unstructured":"Masoudi FA, Calkins H, Kavinsky CJ, Drozda JP Jr, Gainsley P, Slotwiner DJ, et al. 2015 ACC\/HRS\/SCAI left atrial appendage occlusion device societal overview. J Am Coll Cardiol. 2015;66(13):1497\u2013513. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2015.06.028\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"797_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","volume":"64","author":"DR Holmes Jr","year":"2014","unstructured":"Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1\u201312. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2014.04.029\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"797_CR79","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","volume":"61","author":"VY Reddy","year":"2013","unstructured":"Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix feasibility study with watchman left atrial appendage closure technology). J Am Coll Cardiol. 2013;61(25):2551\u20136. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2013.03.035\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"797_CR80","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCEP.108.784272","volume":"1","author":"Z Lu","year":"2008","unstructured":"Lu Z, Scherlag BJ, Lin J, Niu G, Fung KM, Zhao L, et al. Atrial fibrillation begets atrial fibrillation: autonomic mechanism for atrial electrical remodeling induced by short-term rapid atrial pacing. Circ Arrhythm Electrophysiol. 2008;1(3):184\u201392. \n                      https:\/\/doi.org\/10.1161\/CIRCEP.108.784272\n                      \n                    .","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"797_CR81","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/europace\/euu189","volume":"17","author":"ML Hansen","year":"2015","unstructured":"\u2022 Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH, et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace. 2015;17(1):18\u201323. \n                      https:\/\/doi.org\/10.1093\/europace\/euu189\n                      \n                     An informative study looking at the stroke risk in patients with cardioversion without subsequent anticoagulation.","journal-title":"Europace."},{"issue":"12","key":"797_CR82","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0002-9149(98)00704-8","volume":"82","author":"M Berger","year":"1998","unstructured":"Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998;82(12):1545\u20137 A8.","journal-title":"Am J Cardiol"},{"issue":"11","key":"797_CR83","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/S0002-9149(98)00643-2","volume":"82","author":"AV Mattioli","year":"1998","unstructured":"Mattioli AV, Castelli A, Andria A, Mattioli G. Clinical and echocardiographic features influencing recovery of atrial function after cardioversion of atrial fibrillation. Am J Cardiol. 1998;82(11):1368\u201371.","journal-title":"Am J Cardiol"},{"issue":"7","key":"797_CR84","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/0735-1097(94)90652-1","volume":"23","author":"WJ Manning","year":"1994","unstructured":"Manning WJ, Silverman DI, Katz SE, Riley MF, Come PC, Doherty RM, et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol. 1994;23(7):1535\u201340.","journal-title":"J Am Coll Cardiol"},{"issue":"32","key":"797_CR85","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1093\/eurheartj\/ehy148","volume":"39","author":"MD Ezekowitz","year":"2018","unstructured":"Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J, et al. Apixaban compared to heparin\/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39(32):2959\u201371. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehy148\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"10055","key":"797_CR86","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","volume":"388","author":"A Goette","year":"2016","unstructured":"Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995\u20132003. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(16)31474-X\n                      \n                    .","journal-title":"Lancet."},{"issue":"47","key":"797_CR87","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","volume":"35","author":"R Cappato","year":"2014","unstructured":"Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346\u201355. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehu367\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"13","key":"797_CR88","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jacc.2013.04.089","volume":"62","author":"KE Airaksinen","year":"2013","unstructured":"Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013;62(13):1187\u201392. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2013.04.089\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"797_CR89","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1080\/07853890.2016.1267869","volume":"49","author":"A Bah","year":"2017","unstructured":"Bah A, Nuotio I, Gronberg T, Ylitalo A, Airaksinen KE, Hartikainen JE. Sex, age, and time to cardioversion. Risk factors for cardioversion of acute atrial fibrillation from the FinCV study. Ann Med. 2017;49(3):254\u20139. \n                      https:\/\/doi.org\/10.1080\/07853890.2016.1267869\n                      \n                    .","journal-title":"Ann Med"},{"issue":"5","key":"797_CR90","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","volume":"73","author":"EA El-Am","year":"2019","unstructured":"El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol. 2019;73(5):589\u201397. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2018.10.079\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"797_CR91","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1161\/CIRCULATIONAHA.106.638395","volume":"114","author":"A Costa Da","year":"2006","unstructured":"Da Costa A, Thevenin J, Roche F, Romeyer-Bouchard C, Abdellaoui L, Messier M, et al. Results from the Loire-Ardeche-Drome-Isere-Puy-de-Dome (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. Circulation. 2006;114(16):1676\u201381. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.638395\n                      \n                    .","journal-title":"Circulation."},{"issue":"7","key":"797_CR92","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/S0735-1097(00)00635-5","volume":"35","author":"A Natale","year":"2000","unstructured":"Natale A, Newby KH, Pisano E, Leonelli F, Fanelli R, Potenza D, et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol. 2000;35(7):1898\u2013904.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"797_CR93","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.jacep.2016.03.014","volume":"2","author":"W Maskoun","year":"2016","unstructured":"Maskoun W, Pino MI, Ayoub K, Llanos OL, Almomani A, Nairooz R, et al. Incidence of atrial fibrillation after atrial flutter ablation. JACC Clin Electrophysiol. 2016;2(6):682\u201390. \n                      https:\/\/doi.org\/10.1016\/j.jacep.2016.03.014\n                      \n                    .","journal-title":"JACC Clin Electrophysiol"},{"issue":"19","key":"797_CR94","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1408288","volume":"372","author":"A Verma","year":"2015","unstructured":"Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372(19):1812\u201322. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1408288\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"1","key":"797_CR95","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/CIRCEP.109.859116","volume":"3","author":"R Cappato","year":"2010","unstructured":"Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(1):32\u20138. \n                      https:\/\/doi.org\/10.1161\/CIRCEP.109.859116\n                      \n                    .","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"8","key":"797_CR96","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jacc.2009.11.039","volume":"55","author":"S Themistoclakis","year":"2010","unstructured":"Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol. 2010;55(8):735\u201343. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2009.11.039\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"797_CR97","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","volume":"14","author":"H Calkins","year":"2017","unstructured":"\u2022 Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275\u2013444. \n                      https:\/\/doi.org\/10.1016\/j.hrthm.2017.05.012\n                      \n                     The atrial fibrillation ablation consensus statement describing the practicality and indications for ablation.","journal-title":"Heart Rhythm"},{"issue":"25","key":"797_CR98","doi-asserted-by":"publisher","first-page":"e1159","DOI":"10.1161\/CIR.0000000000000503","volume":"135","author":"RA Nishimura","year":"2017","unstructured":"Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 2017;135(25):e1159\u2013e95. \n                      https:\/\/doi.org\/10.1161\/CIR.0000000000000503\n                      \n                    .","journal-title":"Circulation."},{"issue":"36","key":"797_CR99","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739\u201391. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehx391\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"13","key":"797_CR100","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206\u201314. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1300615\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"4","key":"797_CR101","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/RCT.0000000000000232","volume":"39","author":"JR Leach","year":"2015","unstructured":"Leach JR, Elicker B, Yee J, Puppula S, Wisneski JA, Yeh BM. Clot through the heart: paradoxical embolism with Thrombus-in-transit at multidetector computed tomography. J Comput Assist Tomogr. 2015;39(4):598\u2013600. \n                      https:\/\/doi.org\/10.1097\/RCT.0000000000000232\n                      \n                    .","journal-title":"J Comput Assist Tomogr"},{"issue":"7","key":"797_CR102","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","volume":"45","author":"WN Kernan","year":"2014","unstructured":"Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014;45(7):2160\u2013236. \n                      https:\/\/doi.org\/10.1161\/STR.0000000000000024\n                      \n                    .","journal-title":"Stroke."},{"issue":"7","key":"797_CR103","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1093\/ndt\/gfr739","volume":"27","author":"A Stavroulopoulos","year":"2012","unstructured":"Stavroulopoulos A, Aresti V, Zounis C. Right atrial thrombi complicating haemodialysis catheters. A meta-analysis of reported cases and a proposal of a management algorithm. Nephrol Dial Transplant. 2012;27(7):2936\u201344. \n                      https:\/\/doi.org\/10.1093\/ndt\/gfr739\n                      \n                    .","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"797_CR104","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/eurheartj\/ehx551","volume":"39","author":"N Maniwa","year":"2018","unstructured":"Maniwa N, Fujino M, Nakai M, Nishimura K, Miyamoto Y, Kataoka Y, et al. Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction. Eur Heart J. 2018;39(3):201\u20138. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehx551\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"5","key":"797_CR105","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1161\/ATVBAHA.116.308649","volume":"37","author":"PA Lester","year":"2017","unstructured":"Lester PA, Coleman DM, Diaz JA, Jackson TO, Hawley AE, Mathues AR, et al. Apixaban versus warfarin for mechanical heart valve thromboprophylaxis in a swine aortic heterotopic valve model. Arterioscler Thromb Vasc Biol. 2017;37(5):942\u20138. \n                      https:\/\/doi.org\/10.1161\/ATVBAHA.116.308649\n                      \n                    .","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0797-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-019-0797-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0797-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T23:20:51Z","timestamp":1585869651000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-019-0797-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s11912-019-0797-z","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,4]]},"assertion":[{"value":"4 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Isaac <i>B. rhea<\/i> declares that he has no conflict of interest. Alexander R. Lyon has received research funding from Pfizer and has received compensation from Servier, Pfizer, Novartis, Roche, Takeda, Boehringer Ingelheim, Amgen, Clinigen Healthcare, Ferring Pharmaceuticals, Eli Lilly, Bristol-Myers Squibb, Eisai, and Stealth BioTherapeutics for service as a consultant. Michael G. Fradley has received compensation from Novartis for service as a consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"45"}}